### Disease-specific Neuropsychiatric Prodromes in Neurodegeneration What do we know?

Howie Rosen Dorothy Kirsten French Endowed Professor for Parkinsonism and Other Neurodegenerative DIsorders UCSF ADRC UCSF Department of Neurology






# Different neurodegenerative disorders have different profiles of neuropsychiatric changes

Disease A

"All possible" neuropsychiatric symptoms	
	Disease B




# Symptoms of dementia represent the end stage of a long process






#### Studies of pathology confirmed cases support disease specificity for frontotemporal dementia (FTD) vs Alzheimer's disease (AD)





H.J. Rosen, MD; K.M. Hartikainen, MD, PhD; W. Jagust, MD; J.H. Kramer, PsyD; B.R. Reed, PhD; J.L. Cummings, MD; K. Boone, PhD; W. Ellis, MD; C. Miller, MD; and B.L. Miller, MD



Liu et al, Neurology, 2004

	FTLD (n=30)	AD (n=30)	Sample Sx
Social Conduct	80	0	Disinhibition Aggressiveness
Personal Conduct	86	31	Apathy Restlessness
Emotional Blunting	72	13	
Dietary Changes	56	0	Overeating Chewing gum Smoking

Rosen et al, Neurology, 2002



## Dementia with Lewy bodies (DLB) also differs from AD but overlap with some forms of FTD

111 cases with pathologically verified diagnoses and psychosis


DLB


Hallucinations

Shapes, colors

•

- AD/DLB, FTLD, AD
- Hallucinations
  - Sensory modality
  - Content
- Delusions






 Lucy L. Gibson<sup>1</sup>
 Lea T. Grinberg<sup>2,3</sup>
 Dominic ffytche<sup>1</sup>
 Renata E. P. Leite<sup>3</sup>

 Roberta D. Rodriguez<sup>3</sup>
 Renata E. L. Ferretti-Rebustini<sup>4</sup>
 Carlos A. Pasqualucci<sup>3</sup>

 Ricardo Nitrini<sup>3</sup>
 Wilson Jacob-Filho<sup>3</sup>
 Dag Aarsland<sup>1,5</sup>
 Claudia K. Suemoto<sup>3</sup>

#### Naasan et al, Brain, 2021

#### Growing array of studies are prospectively examining the prodrome of neurodegenerative disease





**ARTFL-LEFFTDS** Longitudinal Frontotemporal Lobar Degeneration study (ALLFTD) www.allftd.org

- Prospectively follow participants with high risk for neurodegeneration
- FTLD
  - Autosomal dominant mutations
- DLB
  - Genetic Mutations
  - Genetic Risk variants
  - Clinical syndromes (e.g. RBD)



North American Prodromal For REM Sleep Behavior Disorder Synucleinopathy Cohort (NAPS)



Parkinson's Progression Markers Initiative

Parkinson's Progressive Markers Initiative (PPMI)



### **Prodromal bvFTD often looks like bvFTD**

- Core features
  - Apathy without dysphoria
  - Disinhibition
  - Irritability/agitation
  - Reduced sympathy/empathy
  - Repetitive behaviors
  - Joviality/gregariousness
  - Appetite changes/hyperorality
- Supportive features
  - Executive dysfunction on neuropsych
  - Reduced insight
  - Poor social cognition
- Good sensitivity vs. AD and Controls





#### Proposed research criteria for prodromal behavioural variant frontotemporal dementia


 Megan S. Barker,<sup>1</sup> Reena T. Gottesman,<sup>2</sup> Masood Manoochehri,<sup>1</sup> Silvia Chapman,<sup>1</sup> Brian S. Appleby,<sup>3</sup> Danielle Brushaber,<sup>4</sup> Katrina L. Devick,<sup>4</sup> Bradford C. Dickerson,<sup>5</sup> Kimiko Domoto-Reilly,<sup>6</sup> Julie A. Fields,<sup>7</sup> Leah K. Forsberg,<sup>8</sup> Douglas R. Galasko,<sup>9</sup> Nupur Ghoshal,<sup>10</sup> Jill Goldman,<sup>1,2</sup> Neill R. Graff-Radford,<sup>11</sup> Murray Grossman,<sup>12</sup> Hilary W. Heuer,<sup>13</sup> Ging-Yuek Hsiung,<sup>14</sup> David S. Knopman,<sup>8</sup> John Kornak,<sup>15</sup> Irene Litvan,<sup>9</sup> Ian R. Mackenzie,<sup>16</sup> Joseph C. Masdeu,<sup>17</sup> Mario F. Mendez,<sup>18,19</sup>
 Belen Pascual,<sup>17</sup> Adam M. Staffaroni,<sup>13</sup> Maria Carmela Tartaglia,<sup>20</sup> Bradley F. Boeve,<sup>8</sup> Adam L. Boxer,<sup>13</sup> Howard J. Rosen,<sup>13</sup> Katherine P. Rankin,<sup>13</sup> Stephanie Cosentino,<sup>1,2,21</sup> Katya Rascovsky<sup>12</sup> and Edward D. Huey<sup>1,2,22</sup> on behalf of the ALLFTD Consortium

### But, earliest symptoms may not be very specific

- 66 yo male, family history of FTD due to *MAPT* mutation
  - Age 53 56
    - irritability, easy to anger, bickering with his wife, lost a couple of jobs b/o losing temper
  - By age 56
    - habit of making annoying sounds when eating, clanging fork
    - Eating peanuts every day, insists on having them in the house
    - Got fooled by internet scam
  - By age 60
    - Saying ocially inappropriate things in public (not that bad)
    - Loss of social warmth, empathy
    - Distracted while driving, not always completing tasks at home
  - By age 62
    - Could no longer keep a job because of temper
    - Approaching strangers in street, doesn't notice they're not interested in talking to him
    - Diagnosis of bvFTD

### Very early FTLD may not look like FTD, may not be "mild"

- Delusions typical of schizophrenia
  - Home is bugged
  - Glasses have cameras in them
  - Neurologist killed and replaced (Capgras)
  - Sex god
- Hallucinations (hearing voices)
- Mild exec dysfunction
- Imaging without prominent atrophy
- DSM-V criteria for late life delusional disorder
- Genetic testing showed C9orf72 mutation (couple of years later)
- Developed more symptoms over 3 years
  - Overeating
  - Apathy/social withdrawal
  - motor neuron disease





Khan et al, JNNP, 2012 Block et al, Am J Ger Psych 2016

# NPS in DLB prodrome may not look like fully developed DLB

UDS Clinical Assessment with DLB module

## Hallucinations prominent in dementia stage, as expected

Variable	Symptoms present (%)				
	Controls (n = 53)	AD (n = 78)	DLB (n = 110)	Overall P	Post hoc AD versus DLB
Delusions	2.3	16.7	28.2	.002	.17
Hallucinations	0.0	4.8	35.2	<.001	<.001
Agitation	18.2	42.9	56.3	<.001	.17
Depression	22.7	53.7	69.0	<.001	.10
Anxiety	9.1	45.2	42.3	<.001	.76

MCI-DLB characterized by depressive and anxiety symptoms

Variable	MCI-AD n = 79	MCI-DLB n = 22	Р
Age, years	73.5 (8.8)	75.3 (5.3)	.37
Sex, %M	51.9	68.7	.17
Education, years	15.9 (2.6)	17.0 (2.0)	.09
Hachinski	0.7 (0.8)	0.7 (0.9)	.74
FAQ	2.6 (3.6)	3.4 (4.8)	.42
NPI	4.3 (3.9)	6.3 (5.9)	.06
Depression, %	28.8	64.3	.01
Depression, total	0.4 (0.7)	1.1 (0.9)	.004
Anxiety, %	18.6	46.7	.02
Anxiety, total	0.2 (0.5)	0.7 (0.8)	.005
Apathy, %	27.1	46.7	.14
Apathy, total	0.4 (0.7)	0.8 (1.0)	.09


Galvin et al, Alz & Dem, 2020

### NPS in DLB prodrome <u>may not</u> look like fully developed DLB

#### ...although more typical symptoms may develop as prodrome progresses


For REM Sleep Behavior Disorder		
Mental health		
BAI, score	$8.1 \pm 8.8$	
Anxiety, self-report	142 (39%)	
PHQ-9, score	$5.2 \pm 5.4$	
Depression, <2 years	112 (31%)	
self-report		
PCL-5, score	$12.3\pm15.6$	
PTSD, self-report	48 (13%)	
Obsessive-compulsive	21 (6%)	
disorder		
Developmental disorder	33 (9%)	
Neuropsychiatric inventory		
Delusions	17 (4%)	
Hallucinations	20 (6%)	
Anxiety	80 (22%)	
Apathy/indifference	72 (20%)	
Elliot et al, Ann Clin Trans Neurol, 2023		

**NPS** CONSORTIUM



Hallucinations in ~70% of prodromal patients eventually

#### Mellergard et al, Park & Rel Dis, 2023





### Early syndromes may not be "mild" in DLB either

Prodromes can be long (> 10 years)

- Woman first symptoms of depression age 62
  - Could not do daily chores
  - Recovered after 6 weeks with treatment
- Second episode of depression with suicidality age 69
  - Parkinsonism
  - Sweating at night, constipation
- Depression improved with treatment
  - Parkinsonism improved with changing meds
- Third episode depression age 75
  - No parkinsonism
  - Confusion and hallucinations with aripiprazole
  - Improved with med adjustments


Fujishiro et al, Psychogeriatrics, 2023 McKeith et al, Neurology, 2020






- Age 76
  - Developed dementia
  - Overt parkinsonism, DOPA-responsive
  - Diagnosed with DLB

## Possible model for evolution of NPS over course of illness



## We need to be alert to changes that are not part of standard syndromes in dementia


Frequency and specificity in the prodrome remain to be determined





Resende et al, J Alz Dis, 2022

## Emerging approaches are trying to standardize assessment of prodromal symptoms






#### **EARLY DETECTION**


- At CDR=0.5, bvFTDs performed significantly worse than NCs on all measures, svPPA<NC on all but IRI
- Early deficits < NC in one group only:
  - IRI-EC bvFTD only
  - SNQ22 Break svPPA

## Objective measures of emotional reactivity show promise

#### Elevated facial reactivity to emotional stimuli in prodromal C9orf72 mutation carriers



Abnormal representation of facial musculature in motor cortex



**Healthy Controls** 

C9+ Symptomatic

Courtesy of F Noohi, V Sturm

### Conclusions

- Specific pathological etiologies are associated with specific NPS's
  - Substantial overlap
  - Some differences are in the details of the individual patient's NPS
- Very early prodrome
  - May not be very specific (depression, anxiety, irritability)
  - May include "full blown" psychiatric disorder with functional impact meeting DSM criteria
  - May evolve into more specific patten as prodrome progresses
  - Continuing prospective study is needed
- Future opportunities
  - More standardized informant/self report measures
  - Objective measurements of socioemotional function/processing

### A narrative illustration of loss of empathy

- Bruce Miller, MD
  - A.W. and Mary Margaret Clausen Distinguished Professor in Neurology
  - Director, UCSF Memory and Aging Center
- Pioneer in elucidating the behavioral manifestations of frontal and temporal lobe degeneration
  - Defined modern concept of FTD

- Virginia Sturm, PhD
  - John Douglas French Alzheimer's Foundation Endowed Professor at UCSF in Neurology
  - Director, UCSF Clinical Affective Neuroscience (CAN) lab
- Studies emotional functioning and behavioral and physiological changes in emotional systems in brain disease

